IQSEC2

Across TCGA pan-cancer cohorts, IQSEC2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IQSEC2 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher IQSEC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IQSEC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and OV show a favorable association.

BLCA, UCEC, and HNSC are the cancer types where IQSEC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.180	0.614	<.001	45	view →
UCEC	DFS	Median	All	0.951	0.603	.001	32	view →
HNSC	DFS	Median	II,III,IV	0.126	0.686	<.001	21	view →
OV	DFS	Median	III,IV	0.697	0.149	.038	6	view →
LUSC	DFS	Median	II,III,IV	0.185	0.709	.018	5	view →
SKCM	OS	Median	II,III,IV	1.000	0.722	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IQSEC2–BLCA (OS)

Open the BLCA breakdown →